I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Multifocal Choroiditis with Panuveitis: A Patient’s Guide to MCP
What Is Multifocal Choroiditis with Panuveitis?
MCP is an idiopathic condition, meaning its exact cause remains unknown. It affects the choroid, the RPE, and the vitreous in a distinctive pattern that sets it apart from most other inflammatory eye conditions, and it requires a different management strategy as a result.
MCP creates multiple small, round lesions scattered across the back of the eye, particularly around the macula (the central zone of the retina responsible for sharp, detailed vision) and the mid-periphery. When active, these lesions appear as yellowish or grayish spots at the level of the RPE. As each episode of inflammation settles, the lesions heal into permanent punched-out scars with pigmented edges. A hallmark feature of MCP is the simultaneous presence of inflammatory cells in the vitreous, a finding called vitritis, which reflects inflammation that has spread into the gel of the eye itself.
MCP belongs to a family of inflammatory eye conditions known as white dot syndromes, all of which cause small light-colored lesions at the level of the RPE or choroid. Most white dot syndromes are self-limiting, meaning they resolve without long-term treatment over weeks or months. MCP is a significant exception. It follows a chronic, relapsing course, with inflammation returning repeatedly over many years, and it consistently produces the vitreous inflammation (vitritis) that many related conditions, such as punctate inner choroiditis, typically do not. This chronic pattern is what makes MCP more serious and why sustained treatment is essential rather than optional.
Each episode of active inflammation in MCP attacks the RPE and the choriocapillaris, the fine blood vessel network that nourishes the outer retina. Lesions heal into permanent scars, and because MCP recurs, scarring accumulates with each flare. A particularly serious consequence is that repeated inflammation weakens Bruch's membrane, a thin tissue layer separating the RPE from the choroid. When Bruch's membrane is disrupted, abnormal blood vessels can grow through it into the subretinal space, creating secondary CNV that leaks fluid and blood, rapidly damaging the macula and causing central vision loss that may be difficult or impossible to fully reverse.
MCP shares features with other conditions including punctate inner choroiditis and subretinal fibrosis and uveitis syndrome. Some specialists consider these to represent a spectrum of the same underlying disease process rather than entirely separate disorders. The presence of vitreous inflammation (vitritis) is the key feature that distinguishes MCP from punctate inner choroiditis, which produces similar lesions without significant vitritis. Recognizing where a patient falls within this spectrum helps guide the depth of the diagnostic workup and the level of immunosuppressive therapy required.
Who Is at Risk for MCP?
MCP has a recognizable demographic pattern that can guide earlier recognition and timely referral. Understanding who is most commonly affected helps clinicians and patients stay alert to the diagnosis.
MCP predominantly affects women, with a female-to-male ratio of approximately three to one or higher. The condition most often presents during the third to fourth decades of life, though it can occur across a wider age range. Nearsightedness (myopia) is a common associated finding, with many patients having moderate to high degrees of myopia. The combination of young age, female sex, and significant myopia in a patient presenting with chorioretinal lesions and vitreous inflammation should prompt clinical consideration of MCP. The condition appears more frequently in Caucasian populations, though it has been reported across all ethnic groups.
The underlying cause of MCP is not known. It is not linked to a specific infection, systemic illness, or environmental trigger, and no well-established modifiable risk factors have been identified. Current understanding suggests MCP reflects an immune-mediated process, meaning the body's own immune response targets tissues within the eye, but what initiates this response remains unclear. Because no treatable underlying cause has been identified, management focuses on suppressing the inflammatory process itself rather than eliminating a root cause.
Recognizing the Symptoms of MCP
MCP can cause a range of visual symptoms that shift depending on whether the disease is in an active or quiet phase, how close lesions are to the center of vision, and whether complications such as CNV have developed.
Patients with MCP typically notice blurred vision, floaters, and flashes of light called photopsias. Floaters are particularly prominent during active inflammation because vitreous cells create the sensation of moving specks, threads, or cobwebs drifting across the field of vision. Patients may also develop scotomas, which are areas of reduced or absent vision corresponding to regions of chorioretinal scarring. When lesions occur near or within the macula, even small areas of damage can noticeably affect reading, driving, and other tasks that require sharp central vision.
New distortion of straight lines, known as metamorphopsia, is an important warning sign of developing CNV and should be reported to your retina specialist without delay. A sudden increase in floaters, the appearance of a dark curtain or shadow in the visual field, or a noticeable and rapid drop in vision also warrant urgent evaluation. These symptoms can indicate either a serious flare of inflammation or a new complication, and both benefit greatly from timely intervention to limit permanent damage.
During active episodes, new lesions form, vitreous inflammation intensifies, and visual symptoms worsen. Between episodes, inflammation may partially quiet down, but it rarely resolves completely without treatment. Over time, repeated flares lead to progressively more extensive chorioretinal scarring and a rising cumulative risk of CNV. This chronic, unpredictable behavior is why consistent monitoring and sustained treatment are so important throughout the course of the disease.
How MCP Is Diagnosed
Diagnosing MCP requires a careful combination of clinical examination, advanced retinal imaging, and laboratory testing to confirm the diagnosis and rule out other serious conditions that can appear similar.
During a dilated eye examination, a retina specialist looks for the characteristic pattern of multiple small chorioretinal lesions in various stages of activity. Active lesions appear as yellow or gray spots at the RPE level, while older lesions appear as punched-out atrophic scars with pigmented borders. The vitreous is assessed for cellular inflammation, and the anterior chamber (the fluid-filled space at the front of the eye) is examined for signs of anterior involvement as well. The pattern, distribution, and staging of lesions, combined with vitreous findings and patient demographics, form the clinical foundation of the diagnosis.
Advanced imaging plays a central role in evaluating MCP, detecting complications early, and tracking treatment response. Several tools are typically used together to build a complete picture of the disease.
- OCT (optical coherence tomography) provides detailed cross-sectional images of the retina to detect subretinal fluid, lesion characteristics, and early signs of CNV.
- Fluorescein angiography uses an injected dye to highlight blood vessel activity, showing early darkening of active lesions, late staining as inflammation persists, and leakage from CNV when present.
- Indocyanine green (ICG) angiography uses a different dye to image the choroidal circulation and often reveals more lesions than are visible on clinical examination alone.
- OCT angiography provides detailed views of the blood vessel layers beneath the retina without dye injection and is increasingly used to detect and monitor CNV non-invasively.
- Fundus autofluorescence imaging maps RPE health and the extent of damage across the retina.
- Wide-field imaging allows the peripheral retina beyond the standard clinical view to be evaluated for additional lesions.
Together, these diagnostic tools help characterize the full extent of disease activity, identify complications at their earliest and most treatable stage, and guide treatment decisions over time.
The diagnosis of MCP is one of exclusion, meaning it is made only after other conditions that can produce a similar appearance have been ruled out. Sarcoidosis (a systemic inflammatory disease), tuberculosis, syphilis, and intraocular lymphoma can all cause multifocal chorioretinal lesions that resemble MCP. Laboratory testing, chest imaging, and other studies are ordered based on the clinical presentation to exclude these diagnoses. This thorough evaluation protects patients from a missed diagnosis and ensures that the treatment chosen is appropriate for the actual condition present.
Treatment Approaches for MCP
Treating MCP requires a layered approach that manages active inflammation, prevents disease recurrence, and addresses complications such as CNV when they develop. No single treatment is sufficient on its own, and the regimen is adjusted over time based on how the disease responds.
Corticosteroids are powerful anti-inflammatory medications that can quickly suppress active inflammation during an MCP flare. Depending on the severity and location of the inflammation, they may be delivered as periocular injections (around the outside of the eye), intravitreal injections (directly into the vitreous cavity), or oral tablets. While effective in the short term, corticosteroids are not appropriate for long-term use because they can cause cataracts and raise intraocular pressure (eye pressure) over time. Their primary role in MCP management is to bridge the gap while longer-acting immunosuppressive medications are initiated and begin to take effect.
Sustained immunosuppressive therapy is the cornerstone of long-term MCP management. Research has shown that consistent immunosuppressive treatment is associated with a substantial reduction in the risk of posterior pole complications, including the development of vision-threatening CNV. The medications used most often include mycophenolate mofetil, azathioprine, methotrexate, and cyclosporine, each of which works by calming the immune system's overactive response within the eye. The choice of medication is individualized based on disease activity, severity, the patient's overall health, and prior treatment response. Patients on these medications require regular blood monitoring to check liver function, kidney function, and blood cell counts, ensuring that treatment remains safe over the long term.
When secondary CNV develops, intravitreal anti-VEGF (anti-vascular endothelial growth factor) injections are added to the treatment plan. These medications block the signal that drives abnormal blood vessel growth, reducing leakage from CNV and limiting damage to the overlying retina and macula. Anti-VEGF agents including aflibercept, ranibizumab, and bevacizumab (used off-label) are among the options used in clinical practice. Treating CNV with anti-VEGF alone is not sufficient in MCP. Because CNV in this condition is driven by ongoing inflammation, controlling that inflammation with immunosuppressive therapy is equally necessary. The combination of anti-VEGF treatment and continued immunosuppression addresses both the neovascular complication and its inflammatory driver simultaneously.
For patients whose MCP does not respond adequately to conventional immunosuppressive medications, biologic agents may be considered. Biologics are a class of medications that target specific components of the immune response with greater precision than traditional immunosuppressives, offering more effective inflammation control in difficult cases. Their use in MCP is reserved for more complex or refractory situations and is managed by specialists experienced in treating inflammatory retinal disease. Close follow-up and monitoring for infection and other potential side effects are required whenever biologic therapy is part of the plan.
Long-Term Management and What to Expect
MCP is a long-term condition, and understanding what the journey ahead looks like helps patients stay engaged with their care and make thoughtful decisions about treatment. The goal is not only to treat active flares but to prevent them and limit the accumulation of damage over time.
MCP does not have a permanent cure. Even with effective treatment, some patients experience periodic flares that require adjustments to their regimen. The overarching treatment goal is to achieve sustained control of inflammation so that new lesions do not form, existing scarring remains stable, and the risk of CNV stays as low as possible. Stopping immunosuppressive therapy without guidance from your retina specialist significantly increases the risk of a severe recurrence, which can result in new vision loss that may be difficult to recover.
The long-term visual outlook in MCP depends on how much of the macula is involved, whether CNV develops, and how well inflammation is controlled over time. Patients who maintain consistent immunosuppressive therapy and receive timely treatment for CNV generally have meaningfully better outcomes than those who are undertreated. Some patients preserve good central vision throughout their lives, even when peripheral chorioretinal scarring is present. Early diagnosis and adherence to long-term treatment are the most important contributors to a favorable prognosis.
Regular follow-up with a retina specialist is essential throughout the course of MCP. Monitoring typically includes dilated fundus examination, OCT imaging, and periodic visual field testing. The frequency of visits is guided by disease activity, with more frequent appointments needed during active inflammation or when medications are being adjusted. Patients on long-term immunosuppressive therapy also require routine blood testing to ensure medications remain safe and doses remain appropriate.
Using an Amsler grid at home is a practical way to monitor your central vision between office appointments. An Amsler grid is a simple printed pattern of straight lines with a central dot that, when checked one eye at a time, can reveal new distortion, blurring, or missing areas that may indicate developing CNV or an early flare of inflammation. Any new changes on the grid should be reported to your retina specialist promptly rather than waiting for a scheduled visit, as early intervention consistently produces better outcomes than delayed treatment.
Frequently Asked Questions
Below are answers to some of the most common questions we hear from patients managing a diagnosis of MCP.
MCP can affect one or both eyes, and the timing or severity in each eye does not always match. Some patients have more active disease in one eye while the other remains relatively stable. Because either eye can develop new activity at any time, your retina specialist will examine and image both eyes at every visit, even when symptoms are only present on one side. Bilateral monitoring is a standard part of thorough MCP management and not something to skip during quiet periods.
Active MCP is typically characterized by new lesion formation on imaging, increased vitreous cells, and worsening symptoms such as more floaters, blurring, or new scotomas. Quieter phases show stable imaging findings, absent or minimal vitreous inflammation, and steady vision. However, it is possible for new lesions to form or for CNV to begin developing before symptoms change noticeably, which is why imaging-based monitoring matters even when your vision feels unchanged. Symptoms alone are not a reliable measure of disease activity in MCP.
The duration of treatment is highly individual and cannot be predicted in advance. Some patients require immunosuppressive therapy for several years, while others may need it indefinitely to keep inflammation under control. Decisions about tapering or discontinuing medication are made carefully and only after a sustained period of documented stability on imaging and examination. Stopping immunosuppressives too soon, or without medical supervision, is one of the most common reasons for a severe recurrence with new vision loss. Your retina specialist will guide any treatment changes based on your full clinical picture over time.
Anti-VEGF injections are used for CNV in both conditions, but the overall treatment strategy in MCP is fundamentally different. In MCP, CNV is driven by active inflammation, so immunosuppressive therapy targeting that inflammation is equally important as treating the abnormal blood vessels directly. In age-related macular degeneration, there is no underlying inflammatory driver that requires immunosuppression. Patients with MCP-related CNV need coordinated management of both the neovascular complication and the inflammatory condition simultaneously to achieve lasting control and reduce the risk of recurrence.
Untreated CNV can cause permanent damage to the macula through leakage of fluid and blood into the subretinal space. Over time, this leads to central scotomas, distortion, and reduced visual acuity that may not fully recover even with treatment that begins later. The potential for irreversible central vision loss is precisely why reporting new distortion or sudden visual changes immediately is so important. Daily Amsler grid monitoring at home exists specifically to help patients catch early CNV changes before significant damage has occurred.
MCP requires care from a fellowship-trained retina specialist, and in many cases benefits from involvement of a specialist with particular depth in uveitis, the broad category of inflammatory eye disease to which MCP belongs. The diagnostic evaluation, interpretation of specialized retinal imaging, selection of immunosuppressive medications, and long-term monitoring for complications all require expertise beyond the scope of routine eye care. General ophthalmologists play a valuable role in initial detection and in co-managing patients, but ongoing MCP management is most appropriately led by a specialist experienced with complex inflammatory retinal disease.
Expert Care for Multifocal Choroiditis
New England Retina Associates brings together fellowship-trained vitreoretinal surgeons with extensive experience diagnosing and managing complex inflammatory retinal conditions, including MCP. Our team is equipped with advanced imaging technology and the full spectrum of treatment approaches that long-term MCP management requires, from immunosuppressive therapy to anti-VEGF care for CNV. If you have been diagnosed with MCP, are experiencing symptoms that suggest an inflammatory retinal condition, or have been referred for further evaluation, we are here to provide the specialized care and ongoing support your vision deserves.
30 Years of Care & Commitment
